NL-OMON35806已完成不适用
A PHASE I, RANDOMIZED, DOUBLE BLIND PLACEBO * CONTROLLED, SINGLE AND MULTIPLE DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF OCID 2987 IN HEALTHY MALE SUBJECTS - OCID 2987 SAD/MAD study
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 72
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •- Healthy men
- •- 18-55 years of age, inclusive
- •- BMI 18.0-29.0 kg/m2, inclusive
- •- Non-smoking
排除标准
- •Suffering from: hepatitis B, hepatitis C or HIV/AIDS. In case of participation in another drug study within 60 days before the start of this study or being a blood donor within 60 days from the start of the study. In case of donating more than 1.5 liters of blood (for men) or more than 1.0 liters of blood (for woman) in the 10 months prior the start of this study.
研究者
相似试验
尚未招募
1 期
A STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF TENOFOVIR PIVAFEN FUMARATE (TPF) AND ITS METABOLITES (TENPHENOL AND TENOFOVIR) IN HEALTHY ADULT MALE SUBJECTSCTRI/2023/03/050590Cipla Ltd.,
已完成
不适用
A PHASE I, RANDOMIZED, DOUBLE BLINDED, PLACEBO CONTROLLED STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF SINGLE AND MULTIPLE ASCENDING DOSES OF ORAL GDC-8264 AND THE EFFECT OF FOOD ON THE PHARMACOKINETICS OF GDC-8264 IN HEALTHY VOLUNTEERS1001796910003816Inflammatory Bowel Diseaseirritable bowel syndromeNL-OMON55161Genentech, Inc.114
尚未招募
1 期
A PHASE I STUDY OF HRF-4467, A NEW ANTI-HIV DRUG, TO EVALUATE THE SAFETY AND DRUG LEVELS IN BLOOD (PK), WHILE FASTING AND FED CONDITIONS, IN HEALTHY MALE VOLUNTEERSCTRI/2019/02/017597Hetero Labs Limited
撤回
不适用
A PHASE I, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTICENTER, SINGLE- AND MULTIPLE-ASCENDING-DOSE STUDY TO DETERMINE INITIAL SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF GDC-0134 IN PATIENTS WITH AMYOTROPHIC LATERAL SCLEROSISNL-OMON46763Genentech, Inc.6
招募中
1 期
STUDY TO EVALUATE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF REVN24 IN HEALTHY MALE VOLUNTEERSJPRN-jRCT2071230074Megumi Kai179